Neuro, With different head honchos running the two new CNS divisions of the FDA, with each having somewhat different approaches/agendas/egos, I wonder if there could be some regulatory confusion during the transition period? With Ampakines spanning the full spectrum of both Neurological and Psychiatric indications, won't there have to be some coordination between these two new CNS branches of the FDA when it comes to Ampakines?
News 
Market Data 
Discover 
AI
